Oxford Genetics is a leading synthetic biology company focused on developing technologies to associated with the discovery, development and production of biologics, gene therapies, cell therapies and vaccines.
In August 2018, Oxford Genetics secured a $9.6m investment. The investment comes from existing investor Mercia Technologies PLC and Invesco Perpetua.l
In September 2018, Oxford Genetics and ERS Genomics extended their pre-existing non-exclusive, license agreement for the use of CRISPR gene editing technology. The agreement, which previously allowed Oxford Genetics to supply CRISPR modified cell lines to the US and Europe, has been extended to include the Asia Pacific region.
Documentaries, videos and podcasts
- CRISPRClustered regularly interspaced short palindromic repeats (CRISPR) is a prokaryotic adaptive immune response that provides immunity against foreign nucleic acids, such as viral DNA and bacterial plasmids, through the use of crRNAs (CRISPR RNAs) and associated Cas genes.
- DNAMolecule that encodes the genetic instructions used in the development and functioning of all known living organisms and many viruses